- Previous Close
0.4120 - Open
0.4240 - Bid 0.2974 x 200
- Ask 0.5448 x 200
- Day's Range
0.4101 - 0.4289 - 52 Week Range
0.3440 - 1.5300 - Volume
39,624 - Avg. Volume
235,198 - Market Cap (intraday)
11.812M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5600 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
www.eksobionics.comRecent News: EKSO
View MorePerformance Overview: EKSO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EKSO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EKSO
View MoreValuation Measures
Market Cap
11.62M
Enterprise Value
11.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
0.91
Enterprise Value/Revenue
0.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.21%
Return on Assets (ttm)
-23.53%
Return on Equity (ttm)
-89.52%
Revenue (ttm)
17.93M
Net Income Avi to Common (ttm)
-11.33M
Diluted EPS (ttm)
-0.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
6.49M
Total Debt/Equity (mrq)
47.08%
Levered Free Cash Flow (ttm)
-4.93M